Molecular Biology of the Cell Sign up for new MBC in Press e-TOCs!

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

MBC in Press, published online ahead of print March 1, 2007
Mol. Biol. Cell 10.1091/mbc.E06-09-0833

A more recent version of this article appeared on May 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Material
Right arrow All Versions of this Article:
E06-09-0833v1
18/5/1683    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bakowska, J. C.
Right arrow Articles by Blackstone, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bakowska, J. C.
Right arrow Articles by Blackstone, C.

Submitted on September 18, 2006
Revised on January 30, 2007
Accepted on February 16, 2007

Troyer Syndrome Protein Spartin Is Mono-Ubiquitinated and Functions in EGF Receptor Trafficking

Joanna C. Bakowska,* Henri Jupille,* Parvin Fatheddin,* Rosa Puertollano,{dagger} and Craig Blackstone*

*Cellular Neurology Unit, National Institute of Neurological Disorders and Stroke, and {dagger}Laboratory of Cell Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892

Monitoring Editor: Sandra Lemmon

Troyer syndrome is an autosomal recessive hereditary spastic paraplegia caused by mutation in the spartin (SPG20) gene, which encodes a widely-expressed protein of unknown function. This mutation results in premature protein truncation and thus might signify a loss-of-function disease mechanism. In this study, we have found that spartin is mono-ubiquitinated and functions in degradation of the epidermal growth factor receptor (EGFR). On EGF stimulation, spartin translocates from the cytoplasm to the plasma membrane and colocalizes with internalized EGF-Alexa. Knock-down of spartin by siRNA decreases the rate of EGFR degradation and also affects EGFR internalization, recycling, or both. Furthermore, overexpression of spartin results in a prominent decrease in EGFR degradation. Taken together, our data suggest that spartin is involved in the intracellular trafficking of EGFR and that impaired endocytosis may underlie the pathogenesis of Troyer syndrome.

Address correspondence to: Craig Blackstone (blackstc{at}ninds.nih.gov)




This article has been cited by other articles:


Home page
 Arch NeurolHome page
J. C. Bakowska, H. Wang, B. Xin, C. J. Sumner, and C. Blackstone
Lack of Spartin Protein in Troyer Syndrome: A Loss-of-Function Disease Mechanism?
Arch Neurol, April 1, 2008; 65(4): 520 - 524.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Copyright © 2007 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.